Zoledronic acid 5mg/bag 100ml inj (DrugBank: Zoledronic acid)
10 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 1 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
46 | Malignant rheumatoid arthritis | 0 |
65 | Primary immunodeficiency | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
274 | Osteogenesis Imperfecta | 0 |
299 | Cystic fibrosis | 0 |
333 | Hutchinson-Gilford syndrome | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03924414 (ClinicalTrials.gov) | November 15, 2019 | 2/4/2019 | Trial of Parkinson's And Zoledronic Acid | TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease | Parkinson Disease;Osteoporosis;Parkinsonism | Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo | California Pacific Medical Center Research Institute | National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation | Recruiting | 60 Years | N/A | All | 3500 | Phase 4 | United States |